

Supplemental Figures and Tables




Fig. S1. Gating strategy for major cell lineages in PBMC. (A) Representative 2D CyTOF plots demonstrating gating strategy for defining major leukocyte populations in PBMC. Roman numerals correspond to (B) description of gated subset populations. (C) Cell-surface density (MSI) of HLA-C on unfractionated PBMC in healthy CMV-negative controls across different HLA-C allotypes. Each individual is plotted two times, one for each HLA-C allele. Red bars represent mean values.




Fig. S2. SPADE analysis evaluating expression of NK cell receptors on T cells. SPADE clustering analysis for the same 3 representative samples used in Figs. 5 and 6 (Control, CMV-negative and CMV-reactivated) for evaluating distribution of NK cell receptors expressed across CD4, CD8 and CD4CD8 T cells. Node color represents signal intensity and size represents frequency.




Fig. S3. Continuation of SPADE analysis evaluating expression of NK cell receptors on T cells. SPADE clustering analysis for the same 3 representative samples used in Figs. 5 and 6 (Control, CMV-negative and CMV-reactivated) for evaluating distribution of NK cell receptors expressed across CD4, CD8 and CD4CD8 T cells. Node color represents signal intensity and size represents frequency.

Table S1. Mass cytometry antibody panel

Isotope	Isotope Source	Antibody	Antibody Clone	Antibody Source
112 Cd/Q-dot	DVS Sciences	HLA-DR	Tu36	Invitrogen
115In	Sigma Aldrich	CD57	HCD57	BioLegend
139La	DVS Sciences	CD2	RPA-2.10	BioLegend
141Pr	DVS Sciences	KIR2DS4	FES172	Beckman Coulter
142Nd	DVS Sciences	CD27	O323	BioLegend
143Nd	DVS Sciences	CD19	SJ25-C1	Southern Biotech
144Nd	DVS Sciences	CD122	TU27	BioLegend
145Nd	DVS Sciences	CD4	RPA-T4	DVS Sciences
146Nd	DVS Sciences	CD8	RPA-T8	DVS Sciences
147Sm	DVS Sciences	CD3	UCHT-1	BioLegend
147Sm	DVS Sciences	MIP-1 $\beta$	D21.1351	BD Pharmingen
148Nd	DVS Sciences	CD16	3G8	DVS Sciences
149Sm	DVS Sciences	KIR2DL2/L3/S2	GL183	Beckman Coulter
150Nd	DVS Sciences	CD10	HI10a	BioLegend
151Eu	DVS Sciences	KIR3DL1/S1	Z27.3.7	Beckman Coulter
154Sm	DVS Sciences	LILRB1	HP-F1	Beckman Coulter
155Gd	Trace Sciences	NKp46	9E2	BioLegend
156Gd	DVS Sciences	NKG2D	1D11	BioLegend
157Gd	Trace Sciences	NKG2C	134522	R&D Systems
158Gd	DVS Sciences	2B4	C1.7	BioLegend
159Tb	DVS Sciences	CD33	WM53	BioLegend
160Gd	DVS Sciences	NKp44	P44-8	BioLegend
161Dy	Trace Sciences	NKp30	P30-15	BioLegend
162Dy	DVS Sciences	CD69	FN30	DVS Sciences
163Dy	Trace Sciences	KIR3DL1	DX9	BioLegend
164Dy	DVS Sciences	CD161	HP-3G10	DVS Sciences
165Ho	DVS Sciences	HLA-E	3D12	BioLegend
166Er	DVS Sciences	KIR2DL1	143211	R&D Systems
167Er	DVS Sciences	CD94	DX22	BioLegend
168Er	DVS Sciences	KIR2DL1/S1	EB6.B	Beckman Coulter
169Tm	DVS Sciences	CCR7	G043H7	BioLegend
169Tm	DVS Sciences	CD107a	H4A3	BioLegend
170Er	DVS Sciences	KIR2DL3	180701	R&D Systems
171Yb	DVS Sciences	NKG2A	Z199	Beckman Coulter
172Yb	DVS Sciences	KIR3DL2	DX31	L. Lanier
173Yb	Trace Sciences	KIR2DL4	mAb 33	BioLegend
174Yb	DVS Sciences	CD56	HCD-56	BioLegend
175Lu	DVS Sciences	KIR2DL5	UP-R1	BioLegend
175Lu	DVS Sciences	IFN- $\gamma$	4S.B3	eBioscience
176Yb	DVS Sciences	HLA-C	DT9	V. Braud